title: Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
authors.affiliation: Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Marin
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001157:Arterial Occlusive Diseases / Q000139:chemically induced / Q000628:therapy; D001247:Asthenia / Q000139:chemically induced; D001549:Benzamides / Q000008:administration & dosage; D001856:Bone Marrow Examination; D020732:Cytogenetic Analysis; D004334:Drug Administration Schedule; D057915:Drug Substitution; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism; D020022:Genetic Predisposition to Disease; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib